Business Context and Reporting Period
This Form 8-K, dated December 7, 2018, reports the completion of a reverse merger between OvaScience, Inc. (the "Company") and Millendo Therapeutics, Inc. ("Private Millendo"). Following the transaction, the Company changed its name to Millendo Therapeutics, Inc. and its business focus shifted to developing novel treatments for orphan endocrine diseases. The Company's ticker symbol changed from "OVAS" to "MLND" on the Nasdaq Capital Market, effective December 10, 2018.
Key Financial Metrics and Capital Structure
The filing details significant capital raising activities and equity restructuring rather than operating financial results.
- Pre-Closing Financing: Private Millendo raised approximately $29.5 million in common stock immediately prior to the merger.
- Post-Closing Financing: The Company issued 1,230,158 shares to an institutional investor at $16.258065 per share, generating gross proceeds of approximately $20.0 million.
- Stock Split: A 1-for-15 reverse stock split was effected on December 6, 2018.
- Share Count: Immediately following the merger, 11,684,154 shares were outstanding. Following the post-closing financing, the total outstanding shares were 12,914,312.
- Exchange Ratio: Private Millendo shareholders received 0.0744 shares of Company common stock for each share of Private Millendo common stock.
- Operating Metrics: The filing does not provide revenue, profit, cash flow, or margin data for the reporting period.
Material Changes Versus Prior Period
The filing represents a fundamental transformation of the registrant:
- Corporate Identity: The Company changed its name from OvaScience, Inc. to Millendo Therapeutics, Inc.
- Control and Governance: A change in control occurred. All prior directors (except Dr. Howe) and key officers (including the CEO, CFO, and CSO) resigned. A new board and executive team were appointed, primarily consisting of designees from Private Millendo.
- Business Operations: The Company's primary business is now that of Private Millendo, a biopharmaceutical company, replacing the former operations of OvaScience.
- Capitalization: The capital structure was significantly altered through the reverse stock split, the merger exchange, and the injection of approximately $49.5 million in combined pre- and post-closing financing.
Guidance, Outlook, and Management Commentary
The filing does not contain forward-looking financial guidance, revenue projections, or specific operational milestones. Management commentary is limited to the execution of the merger and the appointment of new leadership.
- Executive Compensation: New employment agreements were established for key officers, including Dr. Julia C. Owens (CEO), Louis J. Arcudi III (CFO), Dr. Pharis Mohideen (CMO), and Jeffery M. Brinza (CAO/GC). These agreements include base salaries, performance bonuses, and stock options with specific vesting schedules and change-in-control acceleration provisions.
- Risks and Contingencies: The filing notes that the resale of post-closing financing shares is subject to a Registration Statement on Form S-3, which the Company may withdraw under certain circumstances. Indemnification agreements were entered into with all directors and officers.
Investor Verification Checklist
- Verify the new ticker symbol "MLND" and CUSIP number 60040X 103 for trading purposes.
- Confirm the total cash raised ($29.5 million pre-closing + $20.0 million post-closing) and its intended use for the orphan endocrine disease pipeline.
- Review the vesting schedules and change-in-control acceleration clauses in the new executive employment agreements.
- Examine the Registration Statement on Form S-4 (Reg. No. 333-227547) for detailed pro forma financial information, which is referenced but not included in this 8-K.
- Monitor the status of the Form S-3 resale registration for the post-closing financing shares.